A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

NCT06530719 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Lung Neoplasms
Lung Cancer, Nonsmall Cell

Interventions

DRUG: Osimertinib mesylate

Sponsor

Jin Ying